Phase II, Randomized,Double-Blind, Single Enter, Controlled Study of Two Doses of Different Formulations of the WRAIR Live Attenuated Tetravalent Dengue Vaccine Compared to a Placebo Control, Administered on a 0-6 Month Schedule, to Healthy Adults.
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2017
At a glance
- Drugs TDENV LAV (Primary)
- Indications Dengue
- Focus Adverse reactions; Pharmacodynamics
- 29 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Jun 2011 Actual end date (Feb 2008) added as reported by ClinicalTrials.gov.
- 26 Jul 2010 Planned end date (1 Dec 2010) added as reported by ClinicalTrials.gov.